NCT06294561View on ClinicalTrials.gov

TGRX-326 Pharmacokinetic Drug Interaction

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

March 4, 2024

Primary Completion Date

May 6, 2024

Study Completion Date

May 6, 2024

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Itraconazole+TGRX-326

healthy subjects will be given TGRX-326 60 mg orally on Day 1, and Itraconazole 200 mg with TGRX-326 60 mg orally on day 11

DRUG

Efavirenz+TGRX-326

healthy subjects will be given TGRX-326 60 mg orally on Day 1, and Efavirenz 600 mg with TGRX-326 60 mg orally on day 20

Trial Locations (1)

210008

Nanjing Drug Tower Hospital, Nanjing

All Listed Sponsors
collaborator

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER

lead

Shenzhen TargetRx, Inc.

INDUSTRY

NCT06294561 - TGRX-326 Pharmacokinetic Drug Interaction | Biotech Hunter | Biotech Hunter